No Data
No Data
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Dyne Therapeutics Price Target Maintained With a $31.00/Share by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Dyne Therapeutics, Inc. (NASDAQ:DYN) Is Largely Controlled by Institutional Shareholders Who Own 53% of the Company
Key Insights Significantly high institutional ownership implies Dyne Therapeutics' stock price is sensitive to their trading actions 51% of the business is held by the top 10 shareholders Insider
Express News | Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $47 Price Target
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Robust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne Therapeutics
No Data